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SUMMARY – Chronic infl ammation has been linked with many cancers. It seems that easily 
available and usual blood infl ammatory markers might serve as a prognostic factor for overall survival 
and disease-free survival in patients with various cancers. Preoperative neutrophil-to-lymphocyte 
 ratio (NLR) and platelet-to-lymphocyte ratio (PLR), as well as hemoglobinemia, thrombocytosis, 
elevated C-reactive protein values, neutropenia and leukocytosis have been shown to aff ect overall 
survival and disease-free survival in patients with colorectal cancer (CRC), however, with controversial 
results. Complete blood count, NLR and PLR were determined in 71 patients with CRC (stages 3 
and 4) after neoadjuvant chemo-radiotherapy and before surgery, treated at Hospital for Tumors in 
Zagreb. Statistical analysis included Mann-Whitney U test, Student’s t-test, univariate and multi-
variate analysis. Th e results of Mann-Whitney U test and Student’s t-test showed that neutrophil 
count (p=0.024), NLR (p=0.003) and PLR (p=0.007) correlated signifi cantly with overall survival. 
However, there was no signifi cant correlation of age, leukocyte, lymphocyte and platelet counts and 
hemoglobin values with overall survival of patients. Furthermore, the same tests showed that leuko-
cyte (p=0.04), neutrophil (p=0.0014) and platelet (p=0.006) counts, NLR (p=0.0006) and PLR 
(p=0.0015), as well as hemoglobin values (p=0.028) correlated signifi cantly with disease-free survival. 
Th e results of univariate analysis showed that unlike PLR, NLR correlated with overall survival and 
disease-free survival (p=0.0002), although the correlation of PLR and disease-free survival almost 
reached signifi cance (p=0.059). Furthermore, the results of univariate analysis showed signifi cant cor-
relation of advanced pathological TNM stage with overall survival. Th ere was no correlation of patient 
age and gender, tumor stage and neoadjuvant chemo-radiotherapy with overall survival and disease-
free survival. Th e results of multivariate analysis showed that NLR (cut-off  value 3.27) and advanced 
pathological TNM stage signifi cantly correlated with disease-free survival but not with overall sur-
vival. It seems that NLR might be an accurate marker for overall survival and disease-free survival in 
CRC patients after neoadjuvant chemo-radiotherapy and before surgery.
Key words: Infl ammation; Blood cell count; Colorectal neoplasms; Disease-free survival; C-reactive 
 protein
Correspondence to: Vanja Vučićević Boras, DDM, Department of 
Oral Medicine, School of Dental Medicine, University of Zagreb, 
Gundulićeva 5, HR-10000 Zagreb, Croatia
E-mail: borasvanja@yahoo.com
Received October 24, 2016, accepted December 18, 2016
Introduction
Colorectal cancer (CRC) is the third cancer in Eu-
rope with fatal outcome. Currently, therapy for locally 
advanced CRC relies on neoadjuvant chemo-radio-
therapy (CRT) in some patients in order to increase 
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the tumor-free resection margin1. Infl ammation with-
in cancers might infl uence future behavior of malig-
nant cells and blood vessels, as well as therapeutic re-
sponse. Some serum biomarkers might give informa-
tion on the level of systemic infl ammation and deter-
mine the future course of disease in many cancer 
patients. Anemia, hemoglobinemia, thrombocytosis 
and elevated C-reactive protein (CRP) values are 
thought to be adverse prognostic factors in various 
malignancies2. Recently, it has been reported that the 
neutrophil/lymphocyte ratio (NLR) and platelet/lym-
phocyte ratio (PLR) might indicate patients that will 
respond poorly to treatments (neoadjuvant CRT) and 
who will have worse disease-free survival (DFS) and 
overall survival (OS) in many cancers such as small cell 
lung carcinoma, esophageal carcinoma, pancreatic ad-
enocarcinoma, and head and neck cancers. Systemic 
meta-analysis in CRC patients has shown that NLR 
has a prognostic value in terms of rational patient 
stratifi cation for further treatment adjustment3. As 
suggested by Kitayama et al.4, tumor shrinkage is de-
pendable on tumor cells and host characteristics, 
therefore, there is a possibility that a lymphocyte-me-
diated immune reaction might result in partial or total 
eradication of tumor cells. Th erefore, lymphocyte 
count in the circulation may improve response to ther-
apy in CRC patients. However, the role of NLR and 
PLR in CRC after CRT and before surgery is yet to be 
established.
Materials and Methods
Prior to this study, participants signed informed 
consent according to Helsinki II. Initially, 150 charts 
of patients having undergone neoadjuvant CRT fol-
lowed by surgery at the Hospital for Tumors, Sestre 
milosrdnice University Hospital Centre in Zagreb, 
were retrieved. Of these, 71 patient charts that includ-
ed data on all study parameters were analyzed for com-
plete blood count, lymphocyte, leukocyte, neutrophil 
and platelet counts, hemoglobin, NLR and PLR. NLR 
was calculated by dividing absolute neutrophil count 
by absolute lymphocyte count. PLR was calculated by 
dividing absolute platelet count by absolute lympho-
cyte count. Primary tumors were staged by use of mag-
netic resonance imaging (MRI). All patients were ir-
radiated and administered concurrent 5-fl uorouracil-
based chemotherapy. Th e mean radiation dose was 45 
Gy (range 45-50.4 Gy) with daily fraction of 1.8. Gy. 
Radiation treatment was performed according to the 
institutional protocols. Pathological tumor staging of 
surgical specimen was performed in accordance with 
the 7th Guidelines of the American Joint Committee 
on Cancer5. Th e primary endpoint of the study was OS 
and DFS. OS was defi ned as the time from the date of 
surgery to death. DFS was defi ned as the time from 
the date of surgery to the date of tumor relapse (local 
recurrence and/or distant metastases) or death. Th e 
secondary endpoint was neoadjuvant chemoradiation 
response as measured by ypTNM staging. In the 
ypTNM staging system, good response was defi ned as 
ypT0 to 2 without lymph node metastases, and poor 
response was defi ned as ypT3 to 4 or with lymph node 
metastases. Statistical analysis included Mann-Whit-
ney U test, Student’s t-test, univariate and multivariate 
analysis. Th e level of signifi cance was set at p<0.05.
Results
Th e results of Mann-Whitney U test and Student’s 
t-test showed that neutrophil count (p=0.024), NLR 
(p=0.003) and PLR (p=0.007) correlated signifi cantly 
with OS (Table 1). However, there was no signifi cant 
correlation of age, leukocyte, lymphocyte and platelet 
counts, and hemoglobin values with OS. Furthermore, 
Table 1. Age, complete blood count and overall survival 








Agea (yrs) 61 (36-79) 56.5 (34-79) 0.68
Leukocytesb 8.16±1.94 9.04±3.42 0.27
Neutrophilsb 5.13±1.6 6.64±2.77 0.024*
Lymphocytesb 2.03±0.55 1.7±0.7 0.138
Plateletsb 310.7±97.58 397.12±239.9 0.059
NLRb 2.76±1.27 4.36±2.18 0.003*
PLRb 166.2±73.56 249.5±124.1 0.007*
Hemoglobinb 129.1±22.2 118.7±26.87 0.23
amedian with range; p value was calculated by Mann-Whitney-U 
test; bmean ± standard deviation; diff erences between groups were 
analyzed by Student’s t-test; NLR = neutrophil-to-lymphocyte 
 ratio; PLR = platelet-to-lymphocyte ratio; *p value lower than 0.05 
set as the level of signifi cance
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Table 3. Univariate analysis of age, sex, adjuvant chemo-radiotherapy, tumor stage, NLR, PLR 
and platelets in the study population
Patient characteristic
Overall survival Disease-free survival
HR 95% CI p-value HR 95% CI p-value
Agea (yrs):
<60
>60 1.09 0.27-4.4 0.89 0.94 0.39-2.22 0.89
Sex:
female




0.15-2.64 0.54 1.93 0.78-4.46 0.16
Stage
3
4 2.89 0.22-169 0.29 1.42 0.28-8.31 0.63
NLR
<3.27
>3.27 4.75 1.4-33.83 0.017* 4.38 2.49-19.24 0.0002*
Platelets
<300
>300 1.12 0.28-4.54 0.87 1.64 0.69-3.9 0.26
PLR
<150
>150 2.05 0.47-8 0.36 2.41 0.97-5.39 0.059
NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; HR = hazard ratio; 95% CI = 95% 
confi dence interval; *p value lower than 0.05 set as the level of signifi cance
Table 2. Age, complete blood count and disease-free 








Agea (yrs) 61 (36-79) 59 (34-79) 0.29
Leukocytesb 7.93±1.92 9.05±2.48 0.04*
Neutrophilsb 4.86±1.44 4.79±2.19 0.0014*
Lymphocytesb 2.07±0.58 1.8±0.54 0.08
Plateletsb 294.9±85.7 380.9±169.9 0.006*
NLRb 2.56±1.17 3.84±1.75 0.0006*
PLRb 155.6±70.04 223.1±96.18 0.0015*
Hemoglobinb 131.7±21.6 118.8±23.49 0.028*
amedian with range; p value was calculated by Mann-Whitney-U 
test; bmean ± standard deviation; diff erences between groups were 
analyzed by Student’s t-test; NLR = neutrophil-to-lymphocyte 
 ratio; PLR = platelet-to-lymphocyte ratio; *p value lower than 0.05 
set as the level of signifi cance
the same tests showed that leukocyte (p=0.04), neutro-
phil (p=0.0014) and platelet (p=0.006) counts, NLR 
(p=0.0006) and PLR (p=0.0015), as well as hemoglo-
bin values (p=0.028) correlated signifi cantly with DFS 
(Table 2). Th e results of univariate analysis showed 
that unlike PLR, NLR correlated with OS and DFS 
(p=0.0002); however, correlation of PLR and DFS al-
most reached signifi cance (p=0.059). Th ere was no 
correlation between patient age and gender, tumor 
stage and neoadjuvant CRT with OS and DFS (Table 
3). Th e results of multivariate analysis showed that 
NLR (cut-off  value 3.27) and advanced pathological 
TNM stage signifi cantly correlated with DFS but not 
with OS (Table 4).
Discussion
Some studies demonstrated that preoperative NLR 
and PLR were signifi cantly increased in CRC patients 
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when compared to healthy controls. Furthermore, 
some authors suggest that NLR might be a useful, 
simple and inexpensive biomarker of response to CRT 
in patients with CRC3,4. Malietzis et al.6 analyzed 13 
studies which evaluated NLR as a sign of treatment 
outcome in patients with CRC. Th ey report that a 
high pre-treatment NLR independently predicted 
shorter survival in all studies (HR 2.08; 95% CI 1.64-
2.64)6. Furthermore, high NLR became a signifi cant 
sign of poor outcome at years 2 and 3, but not in the 
fi rst year of follow up. Furthermore, He et al.7 conclude 
that NLR and CRP were the only independent factors 
for OS and progression-free survival (PFS) in CRC 
patients. Additionally, Li et al.3 analyzed data from 16 
studies in order to associate NLR with OS and PFS in 
CRC patients. Th eir analysis revealed that elevated 
pretreatment NLR correlated with poorer OS and 
PFS in CRC patients. Increased NLR signifi cantly 
correlated with lower tumor diff erentiation and higher 
carcinoembryonic antigen level3. Galizia et al.8 report 
that decreased NLR values correlated signifi cantly 
with increased DFS; along with increased carcinoem-
bryonic antigen levels and Dukes B stage, increased 
levels of NLR independently depicted worse prognosis 
in 503 CRC patients. Th is fi nding is in concordance 
with our results. Even in Dukes A patients, NLR dif-
ferentiated between relapsing and non-relapsing pa-
tients. Preoperative NLR as an inexpensive and easily 
available biomarker might indicate tumor recurrence 
and should be implemented in tailored therapy in ear-
ly stage of CRC. Onozawa et al.9 analyzed 83 patients 
administered oxaliplatin-based chemotherapy for 
stage IV CRC, divided into two groups according to 
NLR; the median survival time of patients with high 
NLR (≥3.0) was signifi cantly worse than that of pa-
tients with low NLR (<3.0; 16.1 months vs. 25.4 
months, p=0.03). Ying et al.10 studied preoperative 
NLR, PLR and lymphocyte-to-monocyte ratio in 205 
surgical CRC patients. Th ey concluded that preopera-
tively elevated NLR was an independent prognostic 
marker for recurrent-free survival, OS and cancer spe-
cifi c survival10. However, Shen et al.11 report no signifi -
cant correlation between NLR and response to neoad-
juvant CRT. Nevertheless, the same authors conclude 
that an increased baseline NLR is a simple, inexpen-
sive and available prognostic marker for OS together 
Table 4. Multivariate analysis of adjuvant chemo-radiotherapy, tumor stage, NLR, PLR, 
platelets and ypTNM in the study population
Patient characteristic
Overall survival Disease-free survival







4 1.89 0.21-17 0.57
NLR:
<3.27
>3.27 4.22 0.99-17.97 0.053 3.49 1.19-10.24 0.024*
Platelets:
<300
>300 0.62 0.22-1.72 0.36
PLR:
<150
>150 2.14 0.61-7.56 0.24
ypTNM staging:
ypT0-2 N0
ypT3-4/N+ 5.02 0.6-41.6 0.14 10.66 2.3-49.49 <0.0026*
NLR = neutrophil-to-lymphocyte ratio; PLR = platelet-to-lymphocyte ratio; Exp(b) = exponential; 95% CI = 
95% confi dence interval; *p value lower than 0.05 set as the level of signifi cance
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with tumor response after neoadjuvant therapy11. All 
these fi ndings are in concordance with our results as 
well. Giakoustidis et al.12 analyzed 169 CRC patients 
that underwent neoadjuvant CRT; 42% of the study 
patients had increased NLR >2.5, which correlated 
with shorter OS but not with DFS. Th is fi nding is par-
tially concordant with our results.
Kim et al.13 report that patients with pre-treatment 
thrombocytosis had decreased 3-year DFS and OS 
when compared with patients with normal pre-treat-
ment platelet counts. Th erefore, the same authors con-
clude that thrombocytosis is a negative indicator in 
these patients, which points to shorter survival in pa-
tients with CRC13. Wei et al.14 showed that the base-
line platelet count correlated with recurrence in 286 
patients with stage II-III CRC receiving adjuvant 
chemotherapy. Th e optimal cut-off  aff ecting recur-
rence was 276×109/L. Kaplan-Meier showed that 
those with baseline platelet count >276×109/L receiv-
ing adjuvant chemotherapy had worse DFS than those 
with baseline platelet count ≤276×109/L, with 5-year 
DFS 66% and 80%, respectively. At the end, CRC pa-
tients receiving adjuvant chemotherapy with baseline 
platelet count >276×109/L had worse prognosis14. Th e 
same correlation between thrombocytosis and DFS 
but not OS was recorded in our patients.
Th e results of this study showed that, irrespective of 
the statistical method employed (except for multivari-
ate analysis), NLR was a signifi cant predictor of DFS 
and OS. It may be that the patient follow up period 
was too short, so the results of multivariate analysis did 
not reach signifi cance regarding NLR and OS (pa-
tients were recruited from the 2011-2015 period). 
However, the results almost reached signifi cance 
(p=0.053).
Th e neutrophil-to-lymphocyte ratio is not a pre-
dictor of pathological response to neoadjuvant CRT, 
i.e. be the NLR high or low, we could not conclude 
whether the patient would have better or worse re-
sponse to neoadjuvant CRT, which is consistent with 
other authors. However, the results of univariate analy-
sis showed signifi cant correlation of advanced patho-
logical TNM stage with both DFS and OS.
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Sažetak
ULOGA PARAMETARA KOMPLETNE KRVNE SLIKE 
U BOLESNIKA S KOLOREKTALNIM KARCINOMOM
M. Solak Mekić, Z. Pedišić, K. Šobat, V. Vučićević Boras, I. Kirac, Lj. Štefančić, M. Šekerija, B. Vrdoljak and D. V. Vrdoljak
Kronična upala je povezana s mnogim karcinomima. Čini se da lako dostupni i uobičajeni upalni biljezi u serumu mogu 
biti prognostički čimbenik za ukupno preživljenje i razdoblje bez bolesti u bolesnika s različitim karcinomima. Prijeoperacij-
ski odnos neutrofi la i limfocita (NLR) te trombocita i limfocita (TLR), kao i hemoglobinemija, trombocitoza, neutropenija 
i leukocitoza su povezani s ukupnim preživljenjem i razdobljem bez bolesti u bolesnika s kolorektalnim karcinomom (KRK), 
doduše, s proturječnim rezultatima. Kompletna krvna slika, NLR i TLR su određeni u 71 bolesnika s KRK (stadij 3 i 4) 
nakon neoadjuvantne kemoradioterapije i prije kirurškog zahvata, koji su liječeni na Klinici za tumore u Zagrebu. Statistička 
analiza je uključivala Mann-Whitneyev U test, Studentov t-test, univarijatnu i multivarijatnu analizu. Rezultati Mann-
-Whitneyeva U testa i Studentova t-testa su pokazali da su broj neutrofi la (p=0,024), NLR (p=0,003) i TLR (p=0,007) zna-
čajno povezani s ukupnim preživljenjem. Ipak, nije bilo značajne povezanosti između dobi, broja leukocita, limfocita i trom-
bocita te hemoglobina s ukupnim preživljenjem bolesnika. Nadalje, isti testovi su pokazali da su broj leukocita (p=0,04), 
neutrofi la (p=0,0014) i trombocita (p=0,006), NLR (p=0,0006) i TLR (p=0,0015), kao i hemoglobin (p=0,028) značajno 
povezani s razdobljem bez bolesti. Rezultati univarijatne analize su pokazali da, za razliku od TLR, NLR korelira s ukupnim 
preživljenjem i preživljenjem bez bolesti, iako je korelacija zamalo postignuta između TLR i razdoblja bez bolesti (p=0,059). 
Nije bilo povezanosti između bolesnikove dobi i spola, stadija tumora i neoadjuvantne kemoradioterapije s ukupnim preživ-
ljenjem i razdobljem bez bolesti. Rezultati multivarijatne analize su pokazali kako NLR (granična vrijednost 3,27) i uznapre-
dovali patološki stadij TNM značajno koreliraju s preživljenjem bez bolesti za razliku od ukupnog preživljenja. Čini se da je 
NLR pouzdan biljeg ukupnog preživljenja kao i preživljenja bez bolesti u bolesnika s KRK nakon neoadjuvantne kemo-
radioterapije i prije kirurškog zahvata.
Ključne riječi: Upala; Krvna slika; Kolorektalni tumori; Preživljenje bez bolesti; C-reaktivni protein
